JZP-6 FDA Approval Status
Last updated by Judith Stewart, BPharm on Jan 30, 2020.
JZP-6 (sodium oxybate oral solution) is a central nervous system depressant intended for use in the treatment of fibromyalgia.
In October 2010, Jazz Pharmaceuticals, Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for JZP-6 had not been approved.
Development timeline for JZP-6
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.